Dysport Articles
Regulatory briefs: Gilead files sofosbuvir; FDA approves Diclegis; Health Canada clears Dysport
9 April 2013
Sharp rise in US FDA approvals of biopharmaceuticals in 2009, highest since 2005, says BII
18 January 2010
Ipsen launch’s Dysport in USA, updates on taspoglutide
29 October 2009
FDA asks for more info on new Botox indication
28 May 2009
Galderma/Ipsen's Azzalure cleared in the UK
16 March 2009
Ipsen's revenues up 6% on new US launches
9 February 2009
Delays for Ipsen BLA as FDA wants more data
12 January 2009
Stock Commentary - Europe - week to Jan 5, 2009
12 January 2009
Ipsen's nine-month sales increase 7%
10 November 2008
Ipsen updates on Dysport progress at FDA
6 October 2008
Ipsen's first-half 2008 profit jumps 42%
8 September 2008
Ipsen's first-half sales beat expectations
11 August 2008
Ipsen reports 8.4% sales growth in 1st qtr
12 May 2008
Ipsen's 2007 operating profit climbs 12%
10 March 2008
Delay to US NDA for Ipsen/Medicis' Reloxin
11 February 2008
Ipsen filed BSA for Dysport with FDA
10 December 2007
Ipsen's 9-month sales rise 5.5% to $994.5M
12 November 2007
Ipsen's six-month net income drops 10%
3 September 2007
Ipsen's 2nd-qtr 2007 sales up 8.1%
13 August 2007
Tanakan may still make reimbursement list
2 April 2007
Ipsen's 1st-half 2006 profit falls 6.6%
18 September 2006
Ipsen's 1st-half 2006 sales rise 7% to $550M
7 August 2006
Ipsen to move into USA via Tercica
31 July 2006
Ipsen extends deadline for Medicis deal
24 April 2006
Ipsen grants US botox rights to Medicis for $194M
27 March 2006
Ipsen fares well since Bourse listing
27 March 2006
Ipsen licenses Reloxin to Medicis
20 March 2006
France's Ipsen sees 8.6% sales growth
16 May 2005
Modest growth for Ipsen in 2002
2 June 2003
Ipsen, Inamed start Ph II botulinum toxin study
13 January 2003
Beaufour-Ipsen to list by 2003
21 November 2000
Elan's NeuroBloc backed by CPMP
6 November 2000
Beaufour Ipsen Outlines Growth Strategy to 2000
7 October 1998
The ABPI's A-Z Of British Medicines Research
29 May 1995
Showing 1-43 of 43 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
